Prazepam

Summary

Prazepam (CHEMBL969) is an approved small molecule (ATC N05BA11); indicated across 1 condition including anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BA11
• Indications: 1 condition
• Chemistry: 324.8 Da · C19H17ClN2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL969
Name	Prazepam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4890
ATC	N05BA11
Molecular formula	C19H17ClN2O
Molecular weight	324.8
InChIKey	MWQCHHACWWAQLJ-UHFFFAOYSA-N

SMILES: C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4

IUPAC name: 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one

Also known as: Centrax, Demetrin, NSC-277179, Prazepam, Prazepam civ, W 4020, W-4020, PRAZEPAM, SID50113069, SID144206168, SID144207274

Patent coverage: 2,965 distinct patent families (12,004 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,987 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).